Literature DB >> 28137869

Akt signaling is critical for memory CD8+ T-cell development and tumor immune surveillance.

Anne Rogel1, Jane E Willoughby1, Sarah L Buchan1, Henry J Leonard1, Stephen M Thirdborough1, Aymen Al-Shamkhani2,3.   

Abstract

Memory CD8+ T cells confer long-term immunity against tumors, and anticancer vaccines therefore should maximize their generation. Multiple memory CD8+ T-cell subsets with distinct functional and homing characteristics exist, but the signaling pathways that regulate their development are ill defined. Here we examined the role of the serine/threonine kinase Akt in the generation of protective immunity by CD8+ T cells. Akt is known to be activated by the T-cell antigen receptor and the cytokine IL-2, but its role in T-cell immunity in vivo has not been explored. Using CD8+ T cells from pdk1K465E/K465E knockin mice, we found that decreased Akt activity inhibited the survival of T cells during the effector-to-memory cell transition and abolished their differentiation into C-X-C chemokine receptor 3 (CXCR3)loCD43lo effector-like memory cells. Consequently, antitumor immunity by CD8+ T cells that display defective Akt signaling was substantially diminished during the memory phase. Reduced memory T-cell survival and altered memory cell differentiation were associated with up-regulation of the proapoptotic protein Bim and the T-box transcription factor eomesodermin, respectively. These findings suggest an important role for effector-like memory CD8+ T cells in tumor immune surveillance and identify Akt as a key signaling node in the development of protective memory CD8+ T-cell responses.

Entities:  

Keywords:  PKB; cancer; cytotoxic T cells; immunotherapy; vaccines

Mesh:

Substances:

Year:  2017        PMID: 28137869      PMCID: PMC5320983          DOI: 10.1073/pnas.1611299114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.

Authors:  Vadim Y Taraban; Tania F Rowley; Aymen Al-Shamkhani
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

Review 2.  Signaling in lymphocyte activation.

Authors:  Doreen Cantrell
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-06-01       Impact factor: 10.005

3.  Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells.

Authors:  Diana M Mitchell; Eugene V Ravkov; Matthew A Williams
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

4.  Intrinsic role of FoxO3a in the development of CD8+ T cell memory.

Authors:  Fanny Tzelepis; Julie Joseph; Elias K Haddad; Susanne Maclean; Renu Dudani; Fabien Agenes; Stanford L Peng; Rafick-Pierre Sekaly; Subash Sad
Journal:  J Immunol       Date:  2012-12-31       Impact factor: 5.422

5.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Rahul Roychoudhuri; David Clever; Alena Gros; Robert L Eil; Eric Tran; Ken-Ichi Hanada; Zhiya Yu; Douglas C Palmer; Sid P Kerkar; Ryan D Michalek; Trevor Upham; Anthony Leonardi; Nicolas Acquavella; Ena Wang; Francesco M Marincola; Luca Gattinoni; Pawel Muranski; Mark S Sundrud; Christopher A Klebanoff; Steven A Rosenberg; Douglas T Fearon; Nicholas P Restifo
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

6.  Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation.

Authors:  Weiguo Cui; Nikhil S Joshi; Aimin Jiang; Susan M Kaech
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

7.  Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.

Authors:  Andrew N Macintyre; David Finlay; Gavin Preston; Linda V Sinclair; Caryll M Waugh; Peter Tamas; Carmen Feijoo; Klaus Okkenhaug; Doreen A Cantrell
Journal:  Immunity       Date:  2011-02-03       Impact factor: 31.745

8.  PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.

Authors:  David K Finlay; Ella Rosenzweig; Linda V Sinclair; Carmen Feijoo-Carnero; Jens L Hukelmann; Julia Rolf; Andrey A Panteleyev; Klaus Okkenhaug; Doreen A Cantrell
Journal:  J Exp Med       Date:  2012-11-26       Impact factor: 14.307

9.  Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates.

Authors:  Surojit Sarkar; Vandana Kalia; W Nicholas Haining; Bogumila T Konieczny; Shruti Subramaniam; Rafi Ahmed
Journal:  J Exp Med       Date:  2008-03-03       Impact factor: 14.307

10.  Functional classification of memory CD8(+) T cells by CX3CR1 expression.

Authors:  Jan P Böttcher; Marc Beyer; Felix Meissner; Zeinab Abdullah; Jil Sander; Bastian Höchst; Sarah Eickhoff; Jan C Rieckmann; Caroline Russo; Tanja Bauer; Tobias Flecken; Dominik Giesen; Daniel Engel; Steffen Jung; Dirk H Busch; Ulrike Protzer; Robert Thimme; Matthias Mann; Christian Kurts; Joachim L Schultze; Wolfgang Kastenmüller; Percy A Knolle
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919

View more
  16 in total

1.  Lack of Sprouty 1 and 2 enhances survival of effector CD8+ T cells and yields more protective memory cells.

Authors:  Hesham M Shehata; Shahzada Khan; Elise Chen; Patrick E Fields; Richard A Flavell; Shomyseh Sanjabi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-20       Impact factor: 11.205

2.  FasL-PDPK1 Pathway Promotes the Cytotoxicity of CD8+ T Cells During Ischemic Stroke.

Authors:  Lizhen Fan; Cun-Jin Zhang; Liwen Zhu; Jian Chen; Zhi Zhang; Pinyi Liu; Xiang Cao; Hailan Meng; Yun Xu
Journal:  Transl Stroke Res       Date:  2020-02-08       Impact factor: 6.829

3.  The role and mechanism of miR-557 in inhibiting the differentiation and maturation of megakaryocytes in immune thrombocytopenia.

Authors:  Yan Wang; Yujie Guo; Xiaolei Zhang; Hui Zhao; Bingbing Zhang; Yi Wu; Jingyu Zhang
Journal:  RNA Biol       Date:  2021-02-15       Impact factor: 4.652

Review 4.  Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond.

Authors:  Jack J Chan; Tira J Y Tan; Rebecca A Dent
Journal:  Ther Adv Med Oncol       Date:  2019-10-09       Impact factor: 8.168

5.  Diverse Roles of Akt in T cells.

Authors:  Leena Abdullah; L Benjamin Hills; Evan B Winter; Yina H Huang
Journal:  Immunometabolism       Date:  2021-01-28

6.  Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival.

Authors:  Junming He; Jun Zhao; Yuhe Quan; Xinlei Hou; Meixiang Yang; Zhongjun Dong
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

7.  Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.

Authors:  Charlotte M Mousset; Willemijn Hobo; Yun Ji; Hanny Fredrix; Valeria De Giorgi; Robert D Allison; Michel G D Kester; J H Frederik Falkenburg; Nicolaas P M Schaap; Joop H Jansen; Luca Gattinoni; Harry Dolstra; Anniek B van der Waart
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

8.  S-15 in combination of Akt inhibitor promotes the expansion of CD45RA-CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells.

Authors:  Benling Xu; Long Yuan; Guangyu Chen; Tiepeng Li; Jinxue Zhou; Chengjuan Zhang; Peng Qin; Musleh M Muthana; Shengdian Wang; Xuexiang Du; Quanli Gao
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722

9.  Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.

Authors:  Qi-Dong Xia; Yang Xun; Jun-Lin Lu; Yu-Chao Lu; Yuan-Yuan Yang; Peng Zhou; Jia Hu; Cong Li; Shao-Gang Wang
Journal:  Cell Prolif       Date:  2020-11-03       Impact factor: 6.831

10.  Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity.

Authors:  Jun Ye; Yue Gao; Ming Ji; Yanfang Yang; Zhaohui Wang; Baolian Wang; Jing Jin; Ling Li; Hongliang Wang; Xiaoyan Xu; Hengfeng Liao; Chunfang Lian; Yaqi Xu; Renjie Li; Tong Sun; Lili Gao; Yan Li; Xiaoguang Chen; Yuling Liu
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.